“Californians have legitimate concerns about access to affordable drugs, but SB 17 does not address them. It is a bad deal for business and does nothing to benefit patients.” – William J. Newell, CEO, Sutro Biopharma & Vice Chairman, California Life Sciences Association.
“As an early-stage company CEO, I’m afraid that SB 17 will increase uncertainty and stifle investment that companies like ours rely on to develop new drugs.”
“Cancer is frightening in the abstract, and even more so when it becomes your reality. Three years ago, I was diagnosed at a relatively young age with late-stage colon cancer and have since gone through extensive treatments.”
CLSA President & CEO Sara Radcliffe pens a letter to the editor of The Sacramento Bee, responding to an op-ed by Sen. Ed Hernandez on SB 17, a bill being deceptively sold under the label of drug pricing transparency.
CLSA Pres. & CEO Sara Radcliffe pens an op-ed in The San Diego Union-Tribune on the strength of California and San Diego’s life sciences industry, the importance of BIO 2017 coming to San Diego, importance of policymakers and stakeholders to sustain and nurture growth of the sector.
CLSA Pres. & CEO Sara Radcliffe pens an op-ed in the Los Angeles Daily News outlining the strength of California life sciences industry, and calling on policymakers and stakeholders to sustain and nurture its growth.
CLSA Pres. & CEO Sara Radcliffe pens an op-ed in the San Jose Mercury News calling on Congress to repeal the Independent Payment Advisory Board (IPAB), a controversial advisory board enacted as part of the ACA, which threatens seniors’ care and could harm biomedical innovation by reducing incentives for investment in new research and product development.
CLSA’s Jenny Carey and EveryLife Foundation for Rare Diseases’ Julia Jenkins pen an op-ed in The Hill on the need enact sound public policies that help tackle the more than 7,000 rare diseases affecting 30 million people, more than half of whom are children.
CLSA Pres. & CEO Sara Radcliffe pens a letter to the editor of The Sacramento Bee responding to their Aug. 11 editorial endorsement of SB 1010, flawed legislation that could enable speculative buying of medicines, creating shortages and leading to growth in “gray markets” where medicine is sold to the highest bidder.
Caroline Loewy, a mother and parent advocate for rare diseases, pens an op-ed in the East Bay Times calling on the policymakers to invest in and promote medical innovation.